文摘
We investigated the association between DRD2 CAn-STR as well as DRD3 Ser9Gly polymorphisms and doses of DAs, especially pramipexole We found that PD patients carrying DRD3 Ser9Gly Gly/Gly genotype took more pramipexole than patients with Ser/Ser and Ser/Gly genotypes Our study indicated that to obtain better therapeutic results, higher doses of pramipexole should be used in patients with Gly/Gly genotype Our results provide some insights into the pharmacogenomics of PD treatment and may help to better understand individual variability in response to DAs